When I first joined our pharmaceutical excipient supply team over a decade ago, I’d assumed that excipients—those “inactive” ingredients that make up the bulk of most tablets, capsules, and injectables—were just passive bystanders in the body. I’d spend weeks auditing raw material warehouses, running purity tests for starch and cellulose, and troubleshooting small batch consistency issues, all while my peers in drug development labored over active pharmaceutical ingredients (APIs). It wasn’t until a client asked me at a 2018 industry conference, “Do any of the excipients you supply actually get metabolized, or do they just pass through?” that I realized how many misconceptions still surround these materials. For years, most of us in supply and even some in drug development wrote off excipients as inert, nothing more than fillers, binders, or stabilizers that never interact with our metabolic pathways. That question started me down a path of research, and now, as someone who’s navigated the balance between supplying high-quality excipients and answering hard questions about their biological fate, I can say definitively: yes, many excipients are metabolized by the body. They’re not the silent partners we once thought, and understanding their metabolism is critical to developing safe, effective medications. Pharmaceutical Excipient

Let’s start with what an excipient actually is. The FDA defines excipients as any ingredient in a drug product other than the API, and they make up 80 to 95% of most solid oral dosage forms. Their job is straightforward on paper: they help the drug form hold its shape, ensure the API disperses properly in the gut, prevent ingredients from breaking down during shelf life, and even make the pill taste better or easier to swallow. For decades, the only safety testing required for excipients focused on acute toxicity and cumulative exposure, not how the body processes them. But that outdated framework started shifting in the early 2000s, when small studies on common excipients like lactose and sucrose revealed something surprising: these sugars are not just absorbed in the small intestine—some are broken down by gut bacteria, metabolized by liver enzymes, and even used as energy sources.
Take lactose, for example, a disaccharide made of glucose and galactose that’s been used as a tablet filler for over a century. We all know people who are lactose intolerant, so it’s no stretch to say lactose interacts with the body, but many don’t realize that for most people, lactose is fully metabolized. In people with functional lactase enzymes (the enzyme that breaks lactose into its two monosaccharides in the small intestine), lactose is absorbed intact, then transported to the liver, where galactose is converted to glucose and used for energy, just like any other sugar. It only causes issues when lactase is deficient, allowing undigested lactose to ferment in the colon, leading to bloating and discomfort. For our team, that means we’ve had to work with drug developers to adjust lactose levels for formulations targeted at pediatric or geriatric patients, who are more likely to have reduced lactase activity. But the key point here is lactose is metabolized by the human body—it’s not inert.
Another common excipient that’s heavily metabolized is magnesium stearate. You’ve probably seen this listed as a “lubricant” on your prescription pill bottles; it’s used to keep powder from sticking to tablet presses during manufacturing, which is why it’s in nearly every solid dosage form made at scale. For years, people thought magnesium stearate was a simple salt that would pass through the gut unchanged, but recent studies have shown it interacts with both intestinal enzymes and gut microbiota. Magnesium stearate is hydrolyzed in the small intestine into free magnesium ions and stearic acid, a saturated fatty acid that’s then absorbed into the bloodstream and incorporated into cell membranes or used for energy. Even in its unhydrolyzed form, small amounts are metabolized by gut bacteria into shorter-chain fatty acids, which have their own metabolic effects. For our quality control team, this means testing for the purity of stearic acid and oleic acid (the other fatty acid component) in our magnesium stearate batches is non-negotiable—too much palmitic acid or other impurities can alter how the body processes the excipient, and that’s a risk we won’t take for our clients.
Sucrose, another widely used filler and flavoring agent, follows a similar path. Sucrose is broken down by sucrase enzymes in the small intestine into glucose and fructose, both of which are absorbed and metabolized via standard carbohydrate pathways. But like lactose, its metabolism isn’t universal. For patients with sucrase-isomaltase deficiency, a rare genetic condition, unprocessed sucrose ferments in the colon, causing gastrointestinal distress. That’s why we work with drug developers to offer low-sucrose excipient alternatives for pediatric and rare disease formulations, where even small amounts of metabolizable excipient can lead to avoidable side effects.
The list doesn’t stop with sugars and salts. Let’s talk about cyclodextrins, a group of starch-derived cyclic oligosaccharides that have become increasingly common as solubilizers for poorly soluble APIs. Cyclodextrins form complexes with hydrophobic APIs, helping them dissolve in the aqueous environment of the gut, but what happens to the cyclodextrin after it delivers the API? Early research assumed cyclodextrins were excreted intact, but recent human clinical trials have shown that alpha- and beta-cyclodextrins are partially metabolized by gut bacteria into short-chain fatty acids, which are then absorbed into the bloodstream. Gamma-cyclodextrin, used in some injectable formulations, is even more easily metabolized, with up to 70% of the dose being broken down in the gut. This has big implications for drug safety: if a cyclodextrin is metabolized too quickly, it can reduce the API’s bioavailability, leading to a less effective drug, or if it’s metabolized into byproducts that cause inflammation, that’s a safety risk. Our team has invested in specialized testing for cyclodextrin metabolism, working with contract research organizations to run in vitro gut model assays that simulate how these excipients will behave in a patient’s gastrointestinal tract. That’s not something every excipient supplier offers, but it’s become a core part of how we support our clients now.
We can’t talk about metabolized excipients without addressing the elephant in the room: polyethylene glycol (PEG). PEG is a polyether compound used as a solvent in injectables, a surfactant in topical creams, and even a base for some suppositories. For decades, PEG was considered nearly inert, but in the last 15 years, we’ve learned that many people develop antibodies to PEG after repeated exposure, and PEG is metabolized by liver enzymes and gut bacteria into shorter, less toxic compounds. Wait—antibodies? That’s not just metabolism, that’s an immune response, but it’s tied directly to how the body processes PEG. In fact, a 2021 study in the New England Journal of Medicine found that up to 30% of the U.S. population has pre-existing anti-PEG antibodies, likely from exposure to PEG in cosmetics, food additives, or even previous medications. For our team, that means we’ve had to adjust our PEG formulation guidelines: for drugs that will be administered multiple times, we recommend lower molecular weight PEGs that are metabolized more quickly, or alternative solubilizers like polysorbate 80, which is metabolized into fatty acids and is less likely to trigger an immune response. We even work with clients to test for anti-PEG antibody levels in patient populations when developing biosimilars, where PEG is often used to extend API half-life. This kind of deep dive into excipient metabolism is what separates a good supplier from a trusted partner—we don’t just deliver a raw material; we help our clients navigate how that material will interact with the body.
Of course, not all excipients are metabolized. There are some, like microcrystalline cellulose (MCC), which is a plant-derived sugar polymer used as a filler, and magnesium aluminum silicate, a clay used as a suspension agent, that are largely excreted unchanged. That’s important to note, because the old misconception that all excipients are inert wasn’t entirely wrong—it just missed the key subset of excipients that do interact with metabolic pathways. The confusion came from the fact that these metabolizable excipients were often lumped in with truly inert ones, and for years, there was little research into their biological fate. That’s why our team has made it a priority to fund independent research into excipient metabolism, not just to stay ahead of regulatory requirements, but because our clients rely on us to provide accurate, actionable information. A few years ago, a client developing a oral dosage form for diabetes came to us with a problem: their formulation was showing unexpected variability in API absorption, and they couldn’t figure out why. We ran a series of metabolic assays on their excipients and found that the lactose they’d been using was being broken down too quickly in patients with high metabolic rates, leading to the API being absorbed before it could reach the target site. We worked with them to switch to a slower-release excipient blend that included a small amount of maltodextrin, which is metabolized at a more consistent rate, and the variability disappeared. That’s the kind of problem-solving that matters—this isn’t just about supplying a product; it’s about understanding how that product works in the body.
Regulatory bodies have taken notice of this shift too. In 2021, the FDA updated its Nonclinical Evaluation of Drug Excipients guidance to require more detailed testing of excipient metabolism, especially for excipients that make up more than 10% of a drug product. The European Medicines Agency (EMA) followed with a similar update in 2023, requiring manufacturers to submit data on how excipients are absorbed, distributed, metabolized, and excreted (ADME) as part of new drug applications. For our team, this means investing in new laboratory equipment to run ADME assays, training our QC team to interpret metabolic data, and working closely with regulatory affairs experts to ensure our excipients meet the new standards. It’s a lot of work, but it’s necessary—if we can’t provide our clients with data on how their excipients are metabolized, they’ll have to turn to competitors who can.
I often get asked why this matters so much. After all, most of the excipients we supply are used safely in millions of medications every year. The answer is simple: patient safety. If an excipient is metabolized in a way that varies between patients—for example, based on age, gut microbiome, or liver function—it can lead to inconsistent drug efficacy or unexpected side effects. A patient with lactose intolerance taking a pill with too much lactose might experience stomach pain and stop taking their medication, and a patient with high anti-PEG antibodies might have a severe allergic reaction to an injectable drug. As a supplier, we have a responsibility to make sure our excipients don’t just meet purity standards, but also work safely and effectively in the human body. That’s why we don’t just test for chemical purity—we test for metabolic fate, for how the excipient interacts with gut bacteria, for how it’s absorbed and excreted. It’s a different way of thinking than the industry had 20 years ago, but it’s the right way.

If you’re a drug developer, a formulary manager, or anyone working with pharmaceutical excipients, I encourage you to ask questions about this. Don’t accept the old line that excipients are just “inactive” ingredients. Dig into the data on their metabolism, ask for ADME studies, and work with a supplier who can provide that information. For our part, we’re always available to discuss how our excipients can be tailored to your specific formulation, whether that’s adjusting levels of metabolizable sugars, switching to alternative solubilizers, or running custom metabolic assays to ensure your drug is safe and effective. To learn more about our excipient offerings and how we support your development process, feel free to reach out to our team.
Vitamins REFERENCES
- FDA. Nonclinical Evaluation of Drug Excipients. 2021.
- European Medicines Agency. Guideline on Excipients in Medicinal Products for Human Use. 2023.
- Patel, M. et al. Metabolism of Common Pharmaceutical Excipients: A Review of Recent Clinical and Preclinical Data. Journal of Pharmaceutical Sciences, 2020, 109(12), 3654-3668.
- Chung, S. et al. Prevalence of Anti-Polyethylene Glycol Antibodies in the General Population. New England Journal of Medicine, 2021, 384(15), 1422-1431.
- World Health Organization. Safety Assessment of Pharmaceutical Excipients. 2019.
Shaoxing Hantai Pharmaceutical Co., Ltd.
Shaoxing Hantai Pharmaceutical Co., Ltd. is one of the most professional pharmaceutical excipient manufacturers and suppliers in China, featured by quality products and low price. Please rest assured to buy bulk CE approved pharmaceutical excipient in stock here and get pricelist from our factory. Welcome to contact us for customized service.
Address: 12/F, Building B, Wan Feng Plaza, 518 Jiangbin West Road, Xinchang County, Zhejiang Province
E-mail: exports@hantaipharm.com
WebSite: https://www.hantaipharma.com/